Pro-Dex (PDEX) to Release Earnings on Thursday

Pro-Dex (NASDAQ:PDEX) is expected to be releasing its Q2 2026 results before the market opens on Thursday, January 29th. Analysts expect the company to announce earnings of $0.59 per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, February 2, 2026 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. Pro-Dex had a return on equity of 23.64% and a net margin of 15.94%.The business had revenue of $18.53 million during the quarter, compared to the consensus estimate of $15.30 million. On average, analysts expect Pro-Dex to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pro-Dex Price Performance

NASDAQ PDEX opened at $41.23 on Wednesday. The company has a 50-day moving average price of $39.74 and a 200-day moving average price of $38.67. Pro-Dex has a 52 week low of $23.47 and a 52 week high of $70.26. The company has a quick ratio of 2.14, a current ratio of 3.73 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $134.41 million, a P/E ratio of 12.31 and a beta of -0.05.

Institutional Trading of Pro-Dex

A number of hedge funds and other institutional investors have recently modified their holdings of PDEX. Geode Capital Management LLC raised its position in shares of Pro-Dex by 93.2% during the second quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier’s stock valued at $2,255,000 after buying an additional 24,927 shares during the last quarter. Punch & Associates Investment Management Inc. grew its stake in Pro-Dex by 42.1% during the third quarter. Punch & Associates Investment Management Inc. now owns 48,608 shares of the medical instruments supplier’s stock valued at $1,645,000 after acquiring an additional 14,408 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Pro-Dex by 67.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier’s stock valued at $1,566,000 after acquiring an additional 14,479 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Pro-Dex by 23.6% in the 2nd quarter. Osaic Holdings Inc. now owns 7,120 shares of the medical instruments supplier’s stock worth $311,000 after purchasing an additional 1,360 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Pro-Dex during the 1st quarter valued at about $321,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pro-Dex in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.